The multivariate analyses reveal that TRM cells are an independent predictive factor for clinical outcomes in lung cancer—emphasizing their significance at the apex of the local immune response, in which TRM concentrations surpass those of effector CD8+ T cells by tenfold and persist beyond 30 days when effector cells are no longer detectable (46). This evidence concerns the gene CD8A and lung carcinoma.